Camp4 Therapeutics Corp (CAMP): Revenue
$3.50M
Year ended 2025-12-31
$4.22M
Trailing 12 months to 2026-06-30
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.50M | +436.5% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $652.0K | +86.3% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $350.0K | n/a | 2025-03-27, From 2023-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $3.50M | +436.5% |
| Marker Therapeutics, Inc. (MRKR) | 2025-12-31 | $3.55M | -46.2% |
| CervoMed Inc. (CRVO) | 2025-12-31 | $4.01M | -58.9% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $3.02M | +71.6% |
| Xenetic Biosciences, Inc. (XBIO) | 2025-12-31 | $2.98M | +19.0% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $4.14M | -8.5% |
| Upstream Bio, Inc. (UPB) | 2025-12-31 | $2.85M | +20.4% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $4.34M | -35.8% |
| Cartesian Therapeutics, Inc. (RNAC) | 2025-12-31 | $2.80M | -92.8% |
Compare CAMP, MRKR, CRVO, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗